Cardiac specific effects of thyroid hormone analogues

Area of Science:

• Endocrinology
• Molecular Biology
• Pharmacology

Background:

• Thyroid hormone analogues are being developed for conditions like obesity and heart failure.
• Current analogues often focus on liver effects, aiming to reduce cardiac and bone side effects.
• Accurate assessment of cardiac effects is crucial for developing safe and effective analogues.

Purpose of the Study:

• To develop a sensitive molecular biomarker assay for thyroid hormone action in cardiac myocytes.
• To evaluate the activity of thyroid hormone receptor (TR) agonists and antagonists on cardiac gene expression.
• To assess the utility of the assay in preclinical studies of thyroid hormone analogues.

Main Methods:

• Developed a biomarker assay measuring the induction of the cardiac-specific α-myosin heavy chain (MHC) gene.
• Utilized reverse transcription and polymerase chain reaction (RT-PCR) to quantify α-MHC primary transcript levels.
• Tested TRα and TRβ selective agonists and TR antagonists in the assay.

Main Results:

• TRα agonists and two TRβ agonists showed significant activity in cardiac myocytes, similar to T3.
• One antagonist (NH-3) did not block T3-mediated α-MHC induction, likely due to poor cellular uptake.
• The assay demonstrated sensitivity in detecting thyroid hormone action at the cardiac myocyte level.

Conclusions:

• The developed α-MHC hnRNA assay is a valuable tool for preclinical assessment of thyroid hormone analogue cardiac effects.
• Predictions of analogue function based solely on structure may be incomplete.
• This assay can aid in the development of analogues with improved therapeutic profiles, minimizing cardiac risks.